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with the other induction drugs namely, vincristine, methotrexate,
decadron, Peg- Asparaginase, ARA-C, doxorubicin was continued.
On day 6 of therapy she developed fever, neutropenia and Bacil-
lus cereus bacteremia. For this broad spectrum antibiotics were
started but no antifungal prophylaxis was begun. During the next
week she developed progressive abdominal pain, rib pain, short-
ness of breath, malaise until on day 14 when RLL infiltrates were
noted on Chest X-Ray. Bronchoscopy was negative for fungal el-
ements. CT scan of chest and abdomen revealed massive hep-
atosplenic infarction and large RLL consolidation (see figure 1).
This was associated with a rapid rise in transaminases and hy-
perammonemia, elevated CRP (see table). Open lung and wedge
biopsy of liver was done revealing subtotal hemorrhagic necrosis
with widespread angioinvasive pleomorphic fungal hyphal forms
(figure 2). In the immediate postoperative period she developed
liver failure and succumbed to irreversible shock. Lung and liver
tissue cultures obtained during biopsy cultured positive for Mucor
species.
Figure 1. Note extensive areas of infarction of spleen and liver segments.
Table 1. Note rapid progression in laboratory values
Date CPK AST ALT T/D Bilirubin
11/3/07 286 53 171 2.1
11/7/07 6616 5075 5292 2.9/6.6
Figure 2. Note angioinvasive fungal hyphae.
Conclusions: This case reveals that mucor can rapidly and fulmi-
nantly invade large vessels and vital organs resulting in occlusive
ischemic damage. Clinicians should have a high index of suspicion
for early diagnosis and surgical intervention to prevent mortality.
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The Use of Antimicrobial Agents in Patients with Acute
Leukaemia with and without Antibacterial Prophylaxis
after Induction Therapy
Karlis Pauksens, David Ullman, Helene Hallböök. Department of
Medical Sciences, Section of Infectious Diseases and Hematology,
Uppsala University Hospital, Akademisks Sjukhuset, Uppsala,
Sweden
Background: Because of an outbreak of Extended Spectrum of Be-
talactamase producing (ESBL) E. coli and Klebsiella pneumonia
emerged in the Hospital, the routine use of fluoroquinolone pro-
phylaxis was questioned. To evaluate the use of fluoroquinolone
prophylaxis and as a background for further recommendations,
this retrospective study was performed in patients with acute
leukaemia after induction therapy at a single-centre. The aim was
to study if there were differences in the use of empiric antibacte-
rial therapy whether prophylaxis was given or not, fever episodes
and infections.
Methods: Fifty-nine episodes of neutropenia following induction
therapy for acute leukaemia were studied during the 2-year pe-
riod, from May 2004 until April 2006, consisting of 55 patients with
4 patients who had relapse of their disease during the study period
and underwent a new induction therapy. The study period was from
the start of induction therapy (day 0) until recovery of neutrophil
count > 0.5x109/L or if the neutrophils did not recover until the
initiation of new chemotherapy or death. Neutropenia was defined
as when neutrophils were <0.5x109/L. If ciprofloxacin prophylaxis
was given, the dose was 500 mg twice daily. For comparison be-
tween different groups the non-parametric Mann-Whitney U-test or
Chi squared test were used when appropriate. A p-value of <0.05
was regarded as statistically significant.
Results: When excluding 16 (27%) of 59 neutropenic periods
on intravenous antibiotics before initiation of induction therapy
(shown separately), 43 neutropenic episodes remained with 29 on
ciprofloxacin prophylaxis and 14 without. These groups matched
each other well. Ciprofloxacin prophylaxis delayed initiation of i.v.
empiric antibiotic therapy with more than 6 days (p<.002), re-
duced the total antibiotics used and days on i.v. antibiotic with
nine days (p<0.002), and febrile episodes (p<0.03). The use of
carbapenems was significantly reduced with 7 days (p<0.004).
The rate of initiating empiric antifungal agents was also reduced
(p<0.012).
Conclusion: In this retrospective single centre study we found that
ciprofloxacin prophylaxis delayed and reduced empiric antibiotic
use and febrile episodes. The results set an important question.
Which strategy is most harmful for the development of resistant
bacterial strains -fluoroquinolone prophylaxis or early initiation
and thus longer duration of empiric antibiotic therapy when no
prophylaxis is given.
81
Risk Factors for Typhlitis in Pediatric Cancer Patients
Itzhak Levy, Hadar Moran, Shai Ashkenazi, Michael Schwartz,
Salvador Fisher, Isaac Yaniv. Pediatric Infectious Diseases Unit,
Schneider Children' s Medical Center of Israel, Petah Tikva, Israel
Background: Typhlitis, is a necrotizing inflammation of the colon,
almost invariably associated with underlying malignancy, intensive
chemotherapy, and severe neutropenia. Currently, limited data are
available on the incidence, outcome, and risk factors of typhlitis in
children with cancer. Previous studies addressing this issue did not
take into account the current changes in cancer treatment proto-
cols and were based on a limited number of cases.
Objectives: To define the epidemiological and clinical features of
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typhlitis in children and to determine risk factors for its develop-
ment.
Methods: We reviewed the medical records of pediatric cancer pa-
tients with typhlitis from 1995 to 2005 for clinical, laboratory and
radiographic findings, and compared them to a control group of
cancer patients hospitalized during the same period without ty-
phlitis.
Results: During the study period 843 patients were diagnosed with
cancer at the Schneider Children' s Medical Center. Among them,
there were 52 episodes of typhlitis in 42 patients (5%), of whom, 32
were treated for hematological malignancies (76%). The incidence
was highest in patients with AML and Burkitt' s lymphoma (15%
and 12%, respectively). The most common clinical findings were
abdominal pain (89%) abdominal tenderness (83%), fever (75%) and
mucositis (58%). Only 50% had severe neutropenia (<100 ANC) on
admission. All patients had abdominal X-RAY while abdominal US
and CT were performed in 23% and 11% of patients, respectively.
The latter imaging methods did not contribute to the diagnosis
or the management of our patients. All patients were treated
conservatively with a 100% survival rate. In multivariate analysis,
mucositis (OR-30.7), history of bone marrow transplantation
OR-58.9) and use of chemotherapy in the two weeks preceding the
typhlitis (OR-12.9) were significantly associated with typhlitis.
Conclusions: The incidence of typhlitis is increasing compared
to previous studies. The highest incidence was among AML and
Burkitt' s lymphoma patients. Although severe neutropenia was
identified as a significant risk factor, it was absent in 50% of the
cases. Mucositis, history of BMT and chemotherapy in the preceding
two weeks were major independent risk factors. Most of pediatric
patients with Typhlitis may be treated conservatively with excel-
lent results. The high survival rate may be attributed to high index
of suspicion and prompt therapy.
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Study of Secondary Infections in Febrile Neutropenic
Patients
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Verbanaz1, Natalia Enriquez1, Jorge Thierer2, Marina Khoury3.
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Aires, Argentina Eduardo Bullorsky Department of Hemathology
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Background: Neutropenic patients may develop secondary infec-
tions (SI) during the treatment of primary infections (PI).
Objectives: To identify predictive variables of secondary infections
among febrile neutropenic patients (FNP) who respond to initial
antibiotic therapy, and analyze whether SI increase mortality.
Methods: FNP with acute leukemia, other haematologic diseases,
solid tumors and drug induced neutropenia were eligible. Only the
first episode of febrile neutropenia of each patient during the
period 1997-2007 was included, and those who did not respond
to initial antibiotic treatment were excluded. Variables assessed
were: age, sex, underlying disease, hematopoietic stem cell trans-
plantation, in-patient at the time of primary infection (IPI), pres-
ence of central catheter, severity of neutropenia (<100 vs. 100-500
PMN/mm3 presence of focus and/or bacteremia at PI, previous an-
timicrobial prophylaxis and initial empiric antibiotic therapy.
Results: Of the 403 FNP with their first episode of febrile neutrope-
nia, 299 responded to initial antibiotic regimen and therefore were
considered for our analysis. SI were observed in 64/299(21.4%).
Forward and backward stepwise multiple logistic regression test
were performed and we obtained a model with 6 predictive vari-
ables: age under 40 (odds ratio (OR) 2.77 [95% CI 1.36-5.63], p=
0.005); acute myeloblastic leukemia (AML)(OR 13.31 [95% CI 6.14-
28.86], p=0.001); severe neutropenia (OR 2.24 [95% CI 1.02-4.93],
p=0.044); focus at PI (OR 2.60 [95% CI 1.22-5.57], p=0.013); bac-
teremia at PI (OR 3.21 [95% CI 1.46-7.05], p=0.004); and IPI (OR
2.36 [95% CI 1.18-4.68], p=0.014). When none of the predictive
variables were present, the probability of SI was 1.3%, and when
the 6 variables were present, it was 95.6%. A score system to pre-
dict the probability of SI was performed. In the multivariate analy-
sis, predictive variables associated with mortality were bacteremia
in PI (OR 7.8 [95% CI 2.4-24], p<0.001) and SI (OR 4.4 [95% CI 1.4-
13], p=0.01). Mortality was 14% in PNF with SI, and 2.5% without SI
(p<0.001).
Conclusions: The predictive variables of SI were: AML, age under
40, severe neutropenia, IPI, and bacteremia and focus in PI. The
presence of bacteremia in the PI and the development of SI were
interpreted as prognostic factors. Our scoring system must be val-
idated in a prospective study.
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Oral Moxifloxacin in the Outpatient Treatment of Low-risk
Children with Fever and Neutropenia
Sérgio Petrilli, Fabianne Carlesse, Janaína Goto, Maria
Aparecida Aguiar, Carlos Alberto Pereira. Pediatric Department
and Infectious Disease Department, Pediatric Oncology Institute,
Federal University of São Paulo, São Paulo, Brazil
Background: Fever in neutropenic patient requires immediate
broad-spectrum antibiotic treatment. However, such patients do
not represent a homogeneous population and the majority of them
are at low risk of developing infectious complication. Several stud-
ies and recent meta-analysis have shown that intravenous antibi-
otics may be substituted by oral antibiotics safely in low risk pa-
tients with febrile neutropenia (FN). Moxifloxacin, a new broad
spectrum quinolone, is an alternative to treat these patients.
Objective: To evaluate the use of oral moxifloxacin in oncologic
pediatric patients with FN.
Methods: We conducted a prospective study in patients submitted
to chemotherapy and FN, from the ages of 3 to 21 years old, with
solid tumors, remission acute lymphoid leukemia (ALL), and lym-
phomas (L) without co-morbidities and treated as outpatient with
oral Moxifloxacina, (15mg/body weight/day -max. 600mg/day) ad-
ministered orally once a day. Safety and adverse events were mon-
itored at the beginning and after each seven days of treatment,
with evaluation of renal and hepatic functions, glicemia and EKG.
Results: Between October 2005 and November 2007, 144 episodes
of FN were included (90 patients). We evaluated 123 episodes (89
patients), being 50.6% males with a median age of 11.3 years.
25.8% corresponded to patients with ALL, 15.7 OS, 12.4% CNS tu-
mors, 9.0% NB, 7.9% Ewing S., 6.7% RMS, 5.6% L, 2.2% Wilms tu-
mors 1.1% PNET, and 13.5% other tumors. 9.8% of the episodes had
a CVC. Analyzing the 106 complete episodes, the average duration
of neutropenia (ANC < 500 cells) was 4.8 days (range, 1-16 days),
the average duration of fever was 2.2 days (range 1-8 days); the av-
erage duration of the treatment was 8.2 days (range 5-21 days).In
the last clinical evaluation, 67% were FUO, 15.1% were MDI and
17.9% were CDI. No patient died. Successful treatment occurred in
84.5% of episodes, 79.6% without modifications (exclusively with
moxifloxacin as outpatient). The reasons for failure of treatment
(19/15,5%) were clinical status deterioration in 4 patients persis-
tent fever (2) and microbiologic evidence (8) an adverse event in
four (vomiting and plateletpenia). No serious adverse events were
observed.
Conclusion: This non-randomized study shows that oral moxiflox-
acin appears effective, safe, convenient, and well-tolerated agent
for the outpatient management of low-risk episodes of chemother-
apy induced FN in pediatric patients in our particular setting.
